All In Biotech

Drug Trial Radar · NCT00966004

A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder

Phase III Study of YM178 - A Placebo-controlled, Double-blind, Group Comparison Study in Patients With Overactive Bladder

Last checked: Nov 20, 2026Latest source record: Oct 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,139 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,139

Actual

Start

Jul 24, 2009

Primary completion

Feb 15, 2010

Study completion Feb 15, 2010

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
Aug 26, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the effect of YM178 in patients with overactive bladder for 12-week administration.

Conditions

  • Urinary Bladder, Overactive

Interventions

  • YM178Drug

    oral

  • PlaceboDrug

    oral

  • tolterodineDrug

    oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in the mean number of micturitions per 24 hoursTime frame: Within a 12-week treatment period

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Chūbu, Japan

  • Site not named

    Kantou, Japan

  • Site not named

    Kinki, Japan

  • Site not named

    Kyushu, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.